-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Hold on CRISPR Therapeutics, Raises Price Target to $45

Benzinga·02/13/2026 16:17:31
Listen to the news
TD Cowen analyst Tyler Van Buren maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Hold and raises the price target from $40 to $45.